Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the fourth quarter of 2023.
- Total revenue increased 8% annually to $1.60 billion in Q4, both on a reported basis and excluding the impact of foreign currency
- Women’s Health revenue increased 7% year-over-year, driven primarily by strong growth in Organon’s fertility products
- Biosimilar revenue jumped 49% from last year as reported, and 48% on an FX-adjusted basis in Q4
- Established Brands revenue rose 3%, despite the impacts of Volume-Based Procurement initiatives and a challenging operating environment in China
- Q4 net income more than doubled to $546 million or $2.13 per share in the three months ended December 2023
- On an adjusted basis, earnings moved up to $0.88 per share in Q4 from $0.81 per share last year
- At $449 million, fourth-quarter adjusted EBITDA was up 18% from the year-ago quarter.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Omnichannel push, margin dynamics in focus as Walmart gears up for Q3 earnings
Walmart Inc. (NYSE: WMT) entered the second half of FY26 navigating a challenging retail landscape marked by tariff-related cost pressure and cautious consumer behavior. At the same time, the company
AMAT Earnings: Applied Materials Q4 adjusted profit drops on lower revenues
Semiconductor equipment maker Applied Materials, Inc. (NASDAQ: AMAT) on Thursday reported a decrease in adjusted earnings for the fourth quarter of fiscal 2025. Adjusted earnings declined to $2.17 per share
Disney’s (DIS) streaming business continues its momentum in Q4 2025
Shares of The Walt Disney Company (NYSE: DIS) fell 9% on Thursday after the company delivered mixed results for the fourth quarter of 2025. While earnings beat expectations, revenues fell
